Summary:We may be one step closer to personalized treatments for alcoholism and alcohol use disorder following results of a recent study, say researchers.
A new study led by scientists at The Scripps Research Institute (TSRI) could help researchers develop personalized treatments for alcoholism and alcohol use disorder.
The research reveals a key difference between the brains of alcohol-dependent versus nondependent rats. When given alcohol, both groups showed increased activity in a region of the brain called the central amygdala (CeA) — but this activity was due to two completely different brain signaling pathways.
TSRI Professor Marisa Roberto, senior author of the new study, said the findings could help researchers develop more personalized treatments for alcohol dependence, as they evaluate how a person’s brain responds to different therapeutics.
The findings were published recently online ahead of print in The Journal of Neuroscience.
Researchers Find Brain’s Alcohol Response ‘Switch’
The new research builds on the Roberto lab’s previous discovery that alcohol increases neuronal activity in the CeA. The researchers found increased activity both nondependent, or naïve, and alcohol-dependent rats.
As they investigated this phenomenon in the new study, Roberto and her colleagues were surprised to find that the mechanisms underlying this increased activity differed between the two groups.
By giving naïve rats a dose of alcohol, the researchers engaged proteins called calcium channels and increased neuronal activity. Neurons fired as the specific calcium channels at play, called L-type voltage-gated calcium channels (LTCCs), boosted the release of a neurotransmitter called GABA. Blocking these LTCCs reduced voluntary alcohol consumption in naïve rats.
But in alcohol-dependent rats, the researchers found decreased abundance of LTCCs on neuronal cell membranes, disrupting their normal ability to drive a dose of alcohol’s effects on CeA activity. Instead, increased neuronal activity was driven by a stress hormone called corticotropin-releasing factor (CRF) and its type 1 receptor (CRF1). The researchers found that blocking CeA CRF1s reduced voluntary alcohol consumption in the dependent rats.
Studying these two groups shed light on how alcohol functionally alters the brain, Roberto explained.
“There is a switch in the molecular mechanisms underlying the CeA’s response to alcohol (from LTCC- to CRF1-driven) as the individual transitions to the alcohol-dependent state,” she said.
The cellular and molecular experiments were led by TSRI Research Associate and study first author Florence Varodayan. The behavioral tests were conducted by TSRI Research Associate Giordano de Guglielmo in the lab of TSRI Associate Professor Olivier George.
Roberto hopes the findings lead to better ways to treat alcohol dependence. Alcohol use disorder appears to have many different root causes, but the new findings suggest doctors could analyze certain symptoms or genetic markers to determine which patients are likely to have CRF-CRF1 hyperactivation and benefit from the development of a novel drug that blocks that activity.